Thanks for your comments @Phaedrus and @dachopper.
Since the ARDS trial, I have been curious as to whether Remestemcel-L combined with corticosteroids may exhibit the same synergistic effects that were observed in the ARDS trial in other indications such as AGvHD.
Steroids will be cheaper as a first-line therapy. However, as we gain more insight regarding mechanism of action and the characteristics that identify patients who are likely to benefit from Rem-L (e.g. high MAP scores, inflammatory biomarkers), it seems quite plausible that doctors could prescribe it as a first-line therapy for those target population - particularly in severe cases. This paper provides a nice summary of recent progress that has been made to identify metrics for stratification of patients for MSC therapies: https://www.sciencedirect.com/science/article/pii/S1465324923010496
2024 Here we go again., page-524
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.025(2.22%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.19 | $1.13 | $8.289M | 7.186M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22569 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 105374 | 2 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.025 ( 2.46 %) |
||||
| Open | High | Low | Volume | ||
| $1.16 | $1.19 | $1.13 | 1229288 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| MSB (ASX) Chart |